[1] Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327: 1379-1391. doi:10.1001/jama.2022.4402. [2] Teerapuncharoen K, Bag R. Chronic thromboembolic pulmonary hypertension[J]. Lung, 2022, 200: 283-299. doi:10.1007/s00408-022-00539-w. [3] Bejjani A, Khairani CD, Assi A, et al. When direct oral anticoagulants should not be standard treatment: JACC State-of-the-Art review[J]. J Am Coll Cardiol, 2024, 83: 444-465. doi:10.1016/j.jacc.2023.10.038. [4] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43: 3618-3731. doi:10.1093/eurheartj/ehac237. [5] Humbert M, Sitbon O, Guignabert C, et al. Treatment of pulmonary arterial hypertension: recent progress and a look to the future[J]. Lancet Respir Med, 2023, 11: 804-819. doi:10.1016/S2213-2600(23)00264-3. [6] Rawal H, Suman A, Bhoite RR, et al. Anticoagulation in pulmonary arterial hypertension: Do we know the answer?[J]. Curr Probl Cardiol, 2021, 46: 100738. doi:10.1016/j.cpcardiol.2020.100738. [7] Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension[J]. Eur Respir J, 1998, 12: 1446-1449. doi:10.1183/09031936.98.12061446. [8] Khan MS, Usman MS, Siddiqi TJ, et al. Is anticoagula-tion beneficial in pulmonary arterial hypertension?[J]. Circ Cardiovasc Qual Outcomes, 2018, 11: e004757. doi:10.1161/CIRCOUTCOMES.118.004757. [9] Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern manage-ment era[J]. Circulation, 2010, 122: 156-163. doi:10.1161/CIRCULATIONAHA.109.911818. [10] Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry[J]. Chest, 2010, 137: 376-387. doi:10.1378/chest.09-1140. [11] Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)[J]. Circulation, 2014, 129: 57-65. doi:10.1161/CIRCULATIONAHA.113.004526. [12] Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension[J]. N Engl J Med, 2013, 369: 809-818. doi:10.1056/NEJMoa1213917. [13] Caldeira D, Loureiro MJ, Costa J, et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis[J]. Can J Cardiol, 2014, 30: 879-887. doi:10.1016/j.cjca.2014.04.016. [14] Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review[J]. Eur Respir J, 2006, 28: 999-1004. doi:10.1183/09031936.06.00015206. [15] Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis[J]. Thromb Res, 2020, 196:251-256. doi:10.1016/j.thromres.2020.08.024. [16] Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension[J]. Chest, 2006, 130: 545-552. doi:10.1378/chest.130.2.545. [17] Lai J, Feng S, Xu S, et al. Effects of oral anticoagulant therapy in patients with pulmonary diseases[J]. Front Cardiovasc Med, 2022, 9:987652. doi:10.3389/fcvm.2022.987652. [18] Henkens IR, Hazenoot T, Boonstra A, et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension[J]. Eur Respir J, 2013, 41: 872-878. doi:10.1183/09031936.00039212. [19] Date N, Nakajima D, Ikeda M, et al. Effect of epoprostenol-induced thrombocytopaenia on lung transplantation for pulmonary arterial hypertension[J]. Eur J Cardiothorac Surg, 2024, 65:ezae108. doi:10.1093/ejcts/ezae108. [20] Roldan T, Rios JJ, Villamanan E, et al. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers[J]. Pulm Circ, 2017, 7: 692-701. doi:10.1177/2045893217721903. [21] Gabriel L, Delavenne X, Bedouch P, et al. Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension[J]. Respiration, 2016, 91: 307-315. doi:10.1159/000445122. [22] Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2021, 57:2002828. doi:10.1183/13993003.02828-2020. [23] Simonneau G, Dorfmuller P, Guignabert C, et al. Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology[J]. Ann Cardiothorac Surg, 2022, 11: 106-119. doi:10.21037/acs-2021-pte-10. [24] Benzidia I, Robitaille C, Abualsaud A, et al. Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension[J]. Thromb Res, 2023, 229:139-145. doi:10.1016/j.thromres.2023.07.002. [25] Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany[J]. Clin Res Cardiol, 2018, 107: 548-553. doi:10.1007/s00392-018-1215-5. [26] Hu S, Tan JS, Liu S, et al. The long-term survival in patients with chronic thromboembolic pulmonary hyperten-sion: experience from a single center in China[J]. J Thromb Thrombolysis, 2022, 53: 926-933. doi:10.1007/s11239-021-02594-1. [27] Sena S, Bulent M, Derya K, et al. Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study[J]. Pulm Circ, 2020, 10: 2045894019873545. doi:10.1177/2045894019873545. [28] Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension[J]. J Thromb Haemost, 2020, 18: 114-122. doi:10.1111/jth.14649. [29] Barati S, Amini H, Ahmadi ZH, et al. Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: A randomized clinical trial[J]. Rev Port Cardiol, 2023, 42: 139-144. doi:10.1016/j.repc.2021.09.023. [30] Ishisaka Y, Watanabe A, Takagi H, et al. Anticoagulation in chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis[J]. Thromb Res, 2023, 231:91-98. doi:10.1016/j.thromres.2023.10.003. [31] Bertoletti L, Mismetti V, Giannakoulas G. Use of anticoagulants in patients with pulmonary hypertension[J]. Hamostaseologie, 2020, 40: 348-355. doi:10.1055/a-1171-3995. [32] Taskar KS, Yang X, Neuhoff S, et al. Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An international transporter consortium perspective[J]. Clin Pharmacol Ther, 2022, 112: 573-592. doi:10.1002/cpt.2670. [33] Margelidon-Cozzolino V, Delavenne X, Catella-Chatron J, et al. Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?[J]. Blood Rev, 2019, 37:100579. doi:10.1016/j.blre.2019.05.003. [34] Huppertz A, Werntz L, Meid AD, et al. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John′s wort should be avoided[J]. Br J Clin Pharmacol, 2018, 84: 2903-2913. doi:10.1111/bcp.13757. [35] Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor[J]. Br J Clin Pharmacol, 2015, 79: 838-846. doi:10.1111/bcp.12541. [36] Washam JB, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF Trial)[J]. Am J Cardiol, 2017, 120: 588-594. doi:10.1016/j.amjcard.2017.05.026. [37] Margelidon-Cozzolino V, Hodin S, Jacqueroux E, et al. In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: type 5-phosphodie-sterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein[J]. J Pharmacol Exp Ther, 2018, 365: 519-525. doi:10.1124/jpet.117.245993. [38] Jacqueroux E, Mercier C, Margelidon-Cozzolino V, et al. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants[J]. Fundam Clin Pharmacol, 2020, 34: 109-119. doi:10.1111/fcp.12504. |